Anzeige
Mehr »
Mittwoch, 23.07.2025 - Börsentäglich über 12.000 News
100% seit April - und trotzdem erst der Anfang? Kupfer wird zum Turbo-Rohstoff des Jahres!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0M84G | ISIN: SE0002190926 | Ticker-Symbol: 2I9
Frankfurt
22.07.25 | 08:06
0,063 Euro
+3,76 % +0,002
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
KAROLINSKA DEVELOPMENT AB Chart 1 Jahr
5-Tage-Chart
KAROLINSKA DEVELOPMENT AB 5-Tage-Chart

Aktuelle News zur KAROLINSKA DEVELOPMENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition raises MSEK 24.6 for the ongoing clinical development of golexanolone2
14.07.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics completes enrollment in part 1 of its phase 2a study with sevuparin158STOCKHOLM, SWEDEN July 14, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Modus Therapeutics has completed patient enrollment on schedule to part...
► Artikel lesen
03.07.Karolinska Development AB (publ): Karolinska Development receives update from Organon concerning OG-621911
KAROLINSKA DEVELOPMENT Aktie jetzt für 0€ handeln
30.06.Karolinska Development AB (publ): Karolinska Development divests shares in portfolio company OssDsign161STOCKHOLM, SWEDEN, June 30, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) divests its remaining shares in the portfolio company OssDsign and thereby strengthens the investment company's...
► Artikel lesen
27.06.Karolinska Development AB (publ): Karolinska Development's portfolio company Modus Therapeutics carries out a fully secured rights issue of SEK 28.3 million1
04.06.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign raises approximately SEK 158 million, announces an updated strategy and revises financial targets36STOCKHOLM, SWEDEN, June 4, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding...
► Artikel lesen
26.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition resumes patient inclusion in its Phase 1b/2a clinical study1
15.05.Karolinska Development AB (publ): Karolinska Development's Annual General Meeting 20252
13.05.Karolinska Development AB (publ): Karolinska Development's portfolio company OssDsign has treated 10,000 patients with OssDsign Catalyst in the US2
07.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition presents data validating novel clinical scale in PBC at EASL 20251
05.05.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition receives grant from The Michael J. Fox Foundation225STOCKHOLM, SWEDEN - May 5, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has been awarded a research grant by The Michael J....
► Artikel lesen
30.04.Karolinska Development AB (publ): Karolinska Development portfolio company OssDsign will change CEO during second half of 20253
30.04.Karolinska Development AB (publ): Interim Report - January-March 2025105STOCKHOLM - 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website. "Developmental...
► Artikel lesen
07.04.Notice of Annual General Meeting in Karolinska Development AB (publ)1
01.04.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition appoints new CEO227STOCKHOLM, SWEDEN - April 1, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) annouces that Viktor Drvota today takes over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota...
► Artikel lesen
21.03.Karolinska Development AB (publ): Karolinska Development Annual Report 2024 published2
18.03.Karolinska Development AB (publ): Karolinska Development's portfolio company Umecrine Cognition provides update on ongoing Phase 1b/2a clinical study250STOCKHOLM, SWEDEN - March 18, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Umecrine Cognition has provided an update regarding the ongoing clinical...
► Artikel lesen
13.03.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio has been granted additional EU patent for drug candidate AC01399STOCKHOLM, SWEDEN March 13, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has been granted patent for its drug candidate AC01 as an...
► Artikel lesen
12.03.Karolinska Development AB (publ): Karolinska Development's portfolio company PharmNovo receives positive FDA feedback prior to IND application for Phase 2a trial201STOCKHOLM, SWEDEN - March 12, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that portfolio company PharmNovo received positive feedback regarding its most advanced drug...
► Artikel lesen
25.02.Karolinska Development AB (publ): Karolinska Development's portfolio company AnaCardio includes first patient in a phase 2a study of its drug candidate AC01149STOCKHOLM, SWEDEN February 25, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has dosed the first patient in the phase 2a part of the...
► Artikel lesen
Weiter >>
31 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1